Calithera Biosciences Reports Second Quarter 2017 Financial Results And Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the second quarter ended June 30, 2017. As of June 30, 2017, cash, cash equivalents and investments totaled $208.2 million.

Back to news